| Heading: |
Glioblastoma: Immunotherapy |
| Question ID: |
1794618 |
| UIN: |
45872 |
| House: |
Commons |
| Date tabled: |
2025-04-17 |
| Asking Member ID: |
4777 |
| Asking Member display name: |
Sarah Owen
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Sarah Owen
|
| Member interest: |
true |
| Question text: |
To ask the Secretary of State for Health and Social Care, when he expects the Medicines and Healthcare products Regulatory Agency will make public their decision on licensing the personalised immunotherapy developed to treat the malignant brain tumour gli |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-29 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Northwest Biotherapeutics has submitted a Marketing Authorization Application to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for DCVax-L, an immunotherapy for glioblastoma. The MHRA is working with the applicant to reac... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |